Advances in the evaluation and management of minimal hepatic encephalopathy

Area of Science:

• Hepatology
• Neuroscience
• Clinical Medicine

Background:

• Minimal hepatic encephalopathy (MHE) is a prevalent neurocognitive disorder in up to 80% of patients with cirrhosis.
• Pathogenesis involves ammonia and oxidative stress, similar to overt hepatic encephalopathy, but with subtle psychomotor deficits detectable by specialized tests.
• MHE significantly impacts quality of life, driving ability, and is linked to increased mortality and progression to overt hepatic encephalopathy.

Purpose of the Study:

• To highlight the clinical significance of MHE in cirrhotic patients.
• To emphasize the need for increased awareness and timely diagnosis and management of MHE.
• To discuss current treatment strategies focused on reducing serum ammonia levels.

Main Methods:

• Review of existing literature on MHE in cirrhosis.
• Discussion of diagnostic challenges and the role of psychometric testing.
• Analysis of the impact of MHE on patient outcomes and quality of life.

Main Results:

• MHE is associated with significant neurocognitive deficits and psychomotor abnormalities in cirrhotic patients.
• MHE negatively affects health-related quality of life and is a risk factor for accidents and mortality.
• Current treatments primarily aim to reduce ammonia levels using agents like lactulose, probiotics, and synbiotics.

Conclusions:

• MHE is an under-recognized but significant condition in cirrhosis, requiring greater clinical attention.
• Prompt identification and management of MHE are essential to mitigate its adverse effects on patients.
• Further research and increased awareness are necessary for the adequate management of MHE in the cirrhotic population.